SLS Research | Milton Maxwell

SLS

SELLAS Life Sciences Group, Inc.

2.2000

+0.1600+7.84%

Dec 16, 4:00:00 PM EST

Upcoming Earnings

Report date

≈ -/-

Earnings Call Transcripts

This Quarter (Q1 '26)

No earnings call transcript available yet

Last Quarter (Q4 '25)

No earnings call transcript available

Key Stats

Market Cap

324.37M

P/E (TTM)

Basic EPS (TTM)

-0.28

Dividend Yield

Recent Filings

8-K

SELLAS 2025 results, cash boost

3/19/26Mar 19, 2026

SELLAS reported 2025 net loss of $26.9M, down from $30.9M, with R&D expenses dropping to $16.0M from $19.1M amid REGAL trial completion. Cash swelled to $71.8M, plus $42.6M from Q1 2026 warrant exercises. Phase 3 REGAL nears 80-event final analysis; SLS009 expansion dosed first patient in frontline AML. Strongest balance sheet ever.

10-K

FY2025 results

3/19/26Mar 19, 2026

SELLAS Life Sciences Group posted FY2025 results dominated by clinical milestones, not financials, with no product revenue disclosed in the 10-K. The REGAL Phase 3 trial for GPS in AML maintenance reached 72 events by December 26, 2025, advancing toward the final 80-event analysis after IDMC's green light. SLS009's Phase 2 in r/r AML hit all endpoints, boasting 33% ORR overall and 44% in AML MR patients at 30 mg BIW, with mOS of 8.9 months crushing historical 2.4 months. No capex or cash flow details provided. Milestones await REGAL readout. Clinical trials carry uncertain outcomes.

8-K

Warrant exercises yield $42.6M

3/11/26Mar 11, 2026

SELLAS Life Sciences Group netted $42.6 million from common stock warrant exercises after December 31, 2025, with $26.5 million by January 8 and $16.1 million more since. Shares outstanding hit 179,536,724 as of March 11, 2026. Cash bolsters runway. No further details disclosed.

8-K

Cash jumps to $98M+

1/8/26Jan 8, 2026

SELLAS ended 2025 with $71.8M in preliminary cash, bolstered by $26.5M from post-year-end warrant exercises. Shares outstanding hit 170,282,026 as of January 7, 2026. Cash runway extends sharply.

10-Q

Q3 FY2025 results

11/12/25Nov 12, 2025

SELLAS Life Sciences posted Q3 FY2025 results ended September 30, 2025, but key financial statements and metrics like revenue, EPS, cash flow, and debt remain undisclosed in the 10-Q filing. No y/y or q/q deltas available for analysis. Non-GAAP metrics not disclosed in the 10-Q. Liquidity and M&A details absent. Clinical-stage biotech burns cash fast. Competition intensifies.

About

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

CEO

Dr. Angelos M. Stergiou M.D., ScD h.c.

IPO

3/12/2008

Website

https://www.sellaslifesciences.com

Employees

Sector

Healthcare

Industry

Biotechnology